Discover insights from the Phase 3 LEAP-012 study evaluating lenvatinib + pembrolizumab + TACE versus double placebo + TACE for patients with intermediate HCC.
In this short expert video, Prof. Arndt Vogel covers the key findings from the publication and places the results into clinical context.
Watch the video for key takeaways and download the infographic for a quick reference.
See the publication in The Lancet: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)02575-3/abstract
Clinical takeaways
- LEAP-012 further supports the approach of combining locoregional therapies with IO-based therapies
- Locoregional therapies combined with IO-based therapies should be more frequently considered in clinical practice, particularly for patients with intermediate HCC, as a potential strategy to downstage or downsize the disease
- Future directions include additional data on overall survival and quality of life, to further define the long-term benefits and clinical applicability